Biolex Therapeutics will work with Genmad A/S, a developer of antibodies, to evaluate whether Biolex’s technology can be used for new antibody manufacturing.

Biolex uses the aquatic plant known as lemma in its LEX System production process.

The contract is the second one Biolex has announced this month.

Genmab is developing a new class of antibodies. The company is based in Denmark.

"We are excited to be working with Genmab as their UniBody technology represents a major potential advancement in the antibody space and gives us the opportunity to further leverage our unique approach to protein production," said Jan Turek, chief executive officer of Biolex. "We are pleased that Genmab, a company with world-class antibody expertise, recognizes the potential advantages of the LEX System approach to protein expression and antibody optimization."

Last week, Biolex announced a contract with Merial Limited to develop animal health products such as vaccines.

Financial terms of the deals were not disclosed.